| MeSH term | MeSH ID | Detail |
|---|---|---|
| Malocclusion | D008310 | 3 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Neuroblastoma | D009447 | 66 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Liver Cirrhosis | D008103 | 67 associated lipids |
| Periodontal Diseases | D010510 | 15 associated lipids |
| Osteitis Deformans | D010001 | 3 associated lipids |
| Dental Pulp Necrosis | D003790 | 6 associated lipids |
| Crohn Disease | D003424 | 12 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Suda T and Miyaura C | [Recent advance in basic research for osteoporosis]. | 2004 | Nippon Rinsho | pmid:15035090 |
| Matsumoto T | [Recent advances in the regulation of bone remodeling]. | 2004 | Nippon Rinsho | pmid:15035093 |
| Chaki O | [Osteoporosis]. | 2006 | Nippon Rinsho | pmid:16689336 |
| Takahashi N et al. | [Osteoprotegerin (OPG)]. | 2010 | Nippon Rinsho | pmid:20960766 |
| Yasuda H | [OPG, anti-rANKL antibody]. | 2005 | Nippon Rinsho | pmid:16164225 |
| Takahashi N et al. | [Osteoprotegerin (OPG)]. | 2005 | Nippon Rinsho | pmid:16149650 |
| Nakamura M et al. | [Osteoclastogenesis and bone resorption]. | 2009 | Nippon Rinsho | pmid:19432105 |
| Masuda H and Tanaka S | [Drugs under development for osteoporosis ]. | 2009 | Nippon Rinsho | pmid:19432120 |
| Suzuki Y | [Clinical significance of biomarkers in diagnosis of metabolic bone diseases]. | 2007 | Nippon Naika Gakkai Zasshi | pmid:18044149 |
| Kotake S et al. | [Molecular mechanism of bone metabolism]. | 2000 | Nippon Naika Gakkai Zasshi | pmid:11215116 |
| Tanaka Y and Okada Y | [Progress in therapy and diagnosis: Hypercalcemia due to parathyroid hormone-related protein producing neoplasms]. | 2007 | Nippon Naika Gakkai Zasshi | pmid:17506302 |
| Kozaki K | [Current concepts of vascular calcification]. | 2005 | Nihon Ronen Igakkai Zasshi | pmid:16408509 |
| Kaneko K and Kawai S | [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis]. | 2011 | Nihon Rinsho Meneki Gakkai Kaishi | pmid:21720102 |
| Tanaka Y et al. | [Mesenchymal stem cells for the treatment and repair of inflammatory arthritis]. | 2015 | Nihon Rinsho Meneki Gakkai Kaishi | pmid:26016635 |
| Shiota J et al. | [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients]. | 2010 | Nihon Jinzo Gakkai Shi | pmid:21254698 |
| Ishizuka K et al. | Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. | 2005 | Neurosci. Lett. | pmid:15814197 |
| Jefferson AL et al. | Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. | 2007 | Neurology | pmid:17389308 |
| Erdogan B et al. | Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. | 2004 | Neurol. Res. | pmid:15327755 |
| Sen O et al. | The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. | 2005 | Neurol. Res. | pmid:15949247 |
| Kokkotou E et al. | Serum correlates of the placebo effect in irritable bowel syndrome. | 2010 | Neurogastroenterol. Motil. | pmid:20028464 |
| Bergestuen DS et al. | Activin A in carcinoid heart disease: a possible role in diagnosis and pathogenesis. | 2010 | Neuroendocrinology | pmid:20720391 |
| Kao SY et al. | Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss. | 2013 | Neurobiol. Dis. | pmid:23607938 |
| Ozkaya O et al. | Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. | 2007 | Nephron Clin Pract | pmid:17259742 |
| Kim HR et al. | The ratio of osteoprotegerin to fetuin-a is independently associated with vascular stiffness in hemodialysis patients. | 2013 | Nephron Clin Pract | pmid:23921088 |
| Kurnatowska I et al. | Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. | 2011 | Nephron Clin Pract | pmid:20861651 |
| Jiang JQ et al. | Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. | 2011 | Nephrology (Carlton) | pmid:21649792 |
| Speer G et al. | Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. | 2008 | Nephrol. Dial. Transplant. | pmid:18450827 |
| Shroff RC et al. | The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. | 2008 | Nephrol. Dial. Transplant. | pmid:18463323 |
| Ford ML et al. | FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. | 2012 | Nephrol. Dial. Transplant. | pmid:21750158 |
| Albalate M et al. | Association between phosphate removal and markers of bone turnover in haemodialysis patients. | 2006 | Nephrol. Dial. Transplant. | pmid:16490746 |
| Schinke T and Karsenty G | Vascular calcification--a passive process in need of inhibitors. | 2000 | Nephrol. Dial. Transplant. | pmid:10978374 |
| Cianciolo G et al. | Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. | 2011 | Nephrol. Dial. Transplant. | pmid:20659908 |
| Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
| Graciolli FG et al. | Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. | 2009 | Nephrol. Dial. Transplant. | pmid:19075196 |
| Avbersek-Luznik I et al. | Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? | 2005 | Nephrol. Dial. Transplant. | pmid:15665031 |
| Sigrist MK et al. | Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. | 2009 | Nephrol. Dial. Transplant. | pmid:19491380 |
| Messa P et al. | Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients. | 2007 | Nephrol. Dial. Transplant. | pmid:17526536 |
| Morena M et al. | A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. | 2009 | Nephrol. Dial. Transplant. | pmid:19574342 |
| Svensson M et al. | Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. | 2012 | Nephrol. Dial. Transplant. | pmid:22172725 |
| Kazama JJ et al. | Circulating osteoprotegerin is not removed through haemodialysis membrane. | 2002 | Nephrol. Dial. Transplant. | pmid:12271009 |
| Nitta K et al. | Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. | 2004 | Nephrol. Dial. Transplant. | pmid:15128884 |
| Coen G et al. | Serum osteoprotegerin and renal osteodystrophy. | 2002 | Nephrol. Dial. Transplant. | pmid:11812872 |
| Talmor-Barkan Y et al. | Low extracellular Ca2+: a mediator of endothelial inflammation. | 2009 | Nephrol. Dial. Transplant. | pmid:19617602 |
| Jablonska E et al. | TRAIL receptors in the serum of patients with B-cell chronic lymphocytic leukemia. | 2008 | Neoplasma | pmid:18190241 |
| Scudla V et al. | The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. | 2010 | Neoplasma | pmid:20099972 |
| Briana DD et al. | Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction. | 2009 | Neonatology | pmid:19365143 |
| Schenk-Braat EA and Bangma CH | [The search for better markers for prostate cancer than prostate-specific antigen]. | 2006 | Ned Tijdschr Geneeskd | pmid:16821452 |
| Lems WF and Bijlsma JW | [Clinical implications of new insights into the regulation of bone resorption]. | 2005 | Ned Tijdschr Geneeskd | pmid:16104110 |
| Araújo AA et al. | Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. | 2013 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:23775504 |
| Kong YY et al. | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. | 1999 | Nature | pmid:10580503 |
| Takayanagi H et al. | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. | 2000 | Nature | pmid:11117749 |
| Boyle WJ et al. | Osteoclast differentiation and activation. | 2003 | Nature | pmid:12748652 |
| Martin TJ and Mundy GR | Bone metastasis: can osteoclasts be excluded? | 2007 | Nature | pmid:17314931 |
| Teitelbaum SL and Ross FP | Genetic regulation of osteoclast development and function. | 2003 | Nat. Rev. Genet. | pmid:12897775 |
| Mundy GR | Metastasis to bone: causes, consequences and therapeutic opportunities. | 2002 | Nat. Rev. Cancer | pmid:12154351 |
| Scholtysek C et al. | PPARβ/δ governs Wnt signaling and bone turnover. | 2013 | Nat. Med. | pmid:23542786 |
| Thompson SW and Tonge D | Bone cancer gain without the pain. | 2000 | Nat. Med. | pmid:10802700 |
| Honore P et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | 2000 | Nat. Med. | pmid:10802707 |
| Movérare-Skrtic S et al. | Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. | 2014 | Nat. Med. | pmid:25306233 |
| Geneviève D et al. | Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome). | 2008 | Nat. Genet. | pmid:18264100 |
| Wagner H | Bone diseases: Interferon regulatory factor-8 suppresses osteoclastogenesis. | 2010 | Nat Rev Rheumatol | pmid:20125173 |
| Flyvbjerg A | Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. | 2010 | Nat Rev Endocrinol | pmid:20098449 |
| Lacey DL et al. | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. | 2012 | Nat Rev Drug Discov | pmid:22543469 |
| Kassi E et al. | Effects of Sideritis euboea (Lamiaceae) aqueous extract on IL-6, OPG and RANKL secretion by osteoblasts. | 2011 | Nat Prod Commun | pmid:22224290 |
| Lin J et al. | Increased generation of Foxp3(+) regulatory T cells by manipulating antigen presentation in the thymus. | 2016 | Nat Commun | pmid:26923114 |
| Daroszewska A and Ralston SH | Mechanisms of disease: genetics of Paget's disease of bone and related disorders. | 2006 | Nat Clin Pract Rheumatol | pmid:16932700 |
| Blair JM et al. | Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. | 2006 | Nat Clin Pract Oncol | pmid:16407878 |
| Huang SH et al. | [Guling tablets promotes the proliferation and mineralization and regulates OPG/RANKL/M-CSF expression of osteoblasts via the p38 MAPK pathway in vitro]. | 2008 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:18676248 |
| Yang XY et al. | [Influence of surface modification of titanium on OPG/RANKL mRNA expression in MG-63 human osteoblast-like cells]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:21868322 |
| Wang Q et al. | [Effect of estrogen on osteoprotegerin, osteoclast differentiation factor and macrophage colony stimulating factor mRNA expressions in ovariectomized rat bone tissue]. | 2006 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:16624776 |
| Zhou XW et al. | [Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:21945761 |
| Wang Y et al. | [Interleukin-4 and osteoprotegerin suppress polyethylene wear debris-induced osteolysis in a murine air pouch model]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:22027773 |
| Wang JZ et al. | [Effect of Epimedium extract on osteoprotegerin and RANKL mRNA expressions in glucocorticoid-induced femoral head necrosis in rats]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:22027774 |
| Dong W et al. | [Effect of alendronate on expressions of osteoprotegerin and receptor activator of nuclear factor κB ligand in mouse osteoblasts]. | 2012 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:23268391 |
| Liu ZF et al. | [Effect of ultrasound on osteoprotegerin and receptor activator nuclear factor kappaB ligand expression during root resorption in rats]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:21602131 |
| Styrkarsdottir U et al. | Multiple genetic loci for bone mineral density and fractures. | 2008 | N. Engl. J. Med. | pmid:18445777 |
| Hirschhorn JN and Gennari L | Bona fide genetic associations with bone mineral density. | 2008 | N. Engl. J. Med. | pmid:18445778 |
| Whyte MP et al. | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12124406 |
| Krane SM | Genetic control of bone remodeling--insights from a rare disease. | 2002 | N. Engl. J. Med. | pmid:12124412 |
| Vegni FE et al. | Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. | 2004 | N. Engl. J. Med. | pmid:14711922 |
| Kiechl S et al. | Denosumab, osteoporosis, and prevention of fractures. | 2009 | N. Engl. J. Med. | pmid:19940304 |
| Riches PL et al. | Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. | 2009 | N. Engl. J. Med. | pmid:19812402 |
| Hofbauer LC and Schoppet M | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12432053 |
| Hofbauer LC et al. | Estrogen therapy and coronary-artery calcification. | 2007 | N. Engl. J. Med. | pmid:17891834 |
| Hofbauer LC et al. | High bone density due to a mutation in LDL-receptor-related protein 5. | 2002 | N. Engl. J. Med. | pmid:12240686 |
| Schneider HG and Sentry J | Multiple myeloma. | 2005 | N. Engl. J. Med. | pmid:15736296 |
| Deftos LJ | Treatment of Paget's disease--taming the wild osteoclast. | 2005 | N. Engl. J. Med. | pmid:16135831 |
| Cundy T et al. | Recombinant osteoprotegerin for juvenile Paget's disease. | 2005 | N. Engl. J. Med. | pmid:16135836 |
| Kurban S et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. | 2008 | Mult. Scler. | pmid:18208894 |
| Weinstock-Guttman B et al. | Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. | 2006 | Mult. Scler. | pmid:17086898 |
| Li N et al. | Inhibitory effects of morinda officinalis extract on bone loss in ovariectomized rats. | 2009 | Molecules | pmid:19513005 |
| Bolon B et al. | Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. | 2001 | Mol. Ther. | pmid:11237676 |
| Chanda D et al. | Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. | 2008 | Mol. Ther. | pmid:18388919 |
| Lee JH et al. | Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. | 2010 | Mol. Pharmacol. | pmid:19828731 |
| Lee ZH et al. | Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. | 2000 | Mol. Pharmacol. | pmid:11093794 |
| Doschak MR et al. | Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. | 2009 Mar-Apr | Mol. Pharm. | pmid:19718808 |
| Yen ML et al. | TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells. | 2008 | Mol. Immunol. | pmid:18206242 |
| Yamada Y et al. | Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. | 2003 | Mol. Genet. Metab. | pmid:14680982 |
| Wang N et al. | Reduced bone turnover in mice lacking the P2Y13 receptor of ADP. | 2012 | Mol. Endocrinol. | pmid:22108801 |
| Dey P et al. | Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. | 2012 | Mol. Endocrinol. | pmid:23028063 |